Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18017339 | 1.00 | DNM2 (0.44) | DNM2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL17985656 | 1.00 | DNM2 (0.44) | DNM2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL17985585 | 0.89 | DNM2 (0.41) | DNM2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL17985582 | 0.89 | DNM2 (0.41) | DNM2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL29486340 | 0.86 | NPC1 (0.52) | DNM2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL18053805 | 0.86 | NPC1 (0.52) | DNM2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL29349616 | 0.86 | NPC1 (0.52) | DNM2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL17985641 | 0.86 | DNM2 (0.46) | DNM2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL29486341 | 0.86 | NPC1 (0.52) | DNM2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL29486342 | 0.86 | NPC1 (0.52) | DNM2NPC1RAB9AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227333-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227333-B2 | Inhibition of OLIG2 activity | GLI2, ING2, GMFG | DNM2 736/4885NPC1 4224/4885RAB9A 3638/4885 |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | DNM2 736/4885NPC1 4224/4885RAB9A 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.